To include your compound in the COVID-19 Resource Center, submit it here.

Epizyme prices $140M follow-on

Cancer company Epizyme Inc. (NASDAQ:EPZM) raised $140 million through the sale

Read the full 115 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE